<DOC>
	<DOCNO>NCT00528710</DOCNO>
	<brief_summary>Fundamentally , trial aim conduct gold-standard test clinical impact SAM-e treatment depress mood general symptom fibromyalgia ( FMS ) . As , salient clinical pathological parameter assess 8-week period 60 patient provide either SAM-e placebo preparation . On basis previous literature , hypothesise patient active treatment group experience moderate significant improvement across clinical measure , gain significantly great report placebo group . All patient provide informed consent . All procedure conduct medical supervision preparation safe use manner propose trial</brief_summary>
	<brief_title>Efficacy S-Adenosylmethionine Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Diagnosis Fibromyalgia medical practitioner Pregnancy , Manic hypomanic condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>S-Adenosylmethionine</keyword>
</DOC>